论文部分内容阅读
Recent studies have demonstrated that the BRAFV600 E mutation is associated with aggressive clinicopathological features of papillary thyroid carcinoma(PTC). However, the BRAF mutation as a prognostic biomarker in papillary thyroid microcarcinoma(PTMC) is